BioCryst Pharmaceuticals Coverage Initiated at JPMorgan Chase & Co. (BCRX)
Research analysts at JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Friday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 43.27% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. Separately, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.33.
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 8.22% on Friday, hitting $13.96. 3,484,373 shares of the company’s stock traded hands. BioCryst Pharmaceuticals has a 1-year low of $4.55 and a 1-year high of $14.58. The stock’s 50-day moving average is $12.21 and its 200-day moving average is $10.62. The company’s market cap is $838.5 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.04. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.32 million. During the same quarter last year, the company posted ($0.23) earnings per share. BioCryst Pharmaceuticals’s revenue was up 79.3% compared to the same quarter last year. On average, analysts predict that BioCryst Pharmaceuticals will post $-0.81 earnings per share for the current fiscal year.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.
Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.